Loading
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Latest filing published 06 Mar 2026 for Generate Biomedicines, Inc., €207k.
Filing timeline
BuySaleMichael Nally
Insider track record
Disclosed buys
1
Disclosed sells
0
Signal history
Closed purchases
Market purchases
1
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- +6.0%Entry US$12.17 · Close 20 Oct 2026 US$12.90
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Michael Nally: trading record in brief
Michael Nally reported a purchase of EUR 206,678 on March 4, 2026 at Generate Biomedicines, Inc., where Michael Nally is Chief Executive Officer. There is no sale. That purchase is one of the 2 filings of the last twelve months.
The record counts 18 filings, published between February 27, 2019 and March 6, 2026: 15 at Merck & Co., Inc. (title EVP, Chief Marketing Officer), 2 at Generate Biomedicines and 1 at PPG Industries Inc (director). It is made of 9 share grants, 7 option exercises and one filing of another kind, in addition to the purchase.
The calendar comes in two blocks: 7 filings in 2019, 7 in 2020 and 2 in 2021, then none before 2026, which has 2. The median publication delay is 2 days.
The count of trades by Nally within 30 days of colleagues at Generate Biomedicines, Inc. is 1, 1 and 1, every one in the same direction. Names in order: Beth Grous, Jane L. Mendillo and Jason Silvers.
Companies and markets linked to Michael Nally
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations18 total
20,000 shares@ US$12.00100.0% of flowCommon StockSEC:0001193125-26-096799:0
Canonical exit: 2 Jun 2026 (T+90)
658,327 sharesCommon StockSEC:0001193125-26-085883:0
164 shares0Common StockSEC:0001209191-21-027076:0
7,127 shares@ US$72.6229.1% of flowCommon StockSEC:0001127602-21-008567:0
2,287 shares@ US$75.8918.2% of flowCommon StockSEC:0001127602-20-028034:0
995 shares@ US$75.897.9% of flowCommon StockSEC:0001127602-20-028034:1
1,298 shares@ US$77.6710.7% of flowCommon StockSEC:0001127602-20-015653:0
565 shares@ US$77.674.6% of flowCommon StockSEC:0001127602-20-015653:1
2,345 shares@ US$76.8619.2% of flowCommon StockSEC:0001127602-20-015653:2
1,020 shares@ US$76.868.4% of flowCommon StockSEC:0001127602-20-015653:3
3,328 shares@ US$76.5626.7% of flowCommon StockSEC:0001127602-20-009156:0
2,287 shares0Common StockSEC:0001225208-19-014015:0
652 shares@ US$85.104.8% of flowCommon StockSEC:0001225208-19-014015:1
1,811 shares0Common StockSEC:0001104659-19-028977:0
516 shares@ US$78.333.5% of flowCommon StockSEC:0001104659-19-028977:1
1,298 shares0Common StockSEC:0001104659-19-027584:0
370 shares@ US$80.002.6% of flowCommon StockSEC:0001104659-19-027584:1
1,527 shares@ US$80.3810.4% of flowCommon StockSEC:0001225208-19-003896:0
18 of 18 declarations
